A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Active, not recruiting · NCT05568459
Conditions: Hemophilia B
At a glance
- Research payments reported, 2025
- $305,992
- U.S. investigators named
- 12
- Sites paid
- 11
- Planned or actual enrollment
- 11
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Non-Interventional (other)
- Dates
- Started 2024-01-17; completion 2026-11-20
- Results posted
- Not yet
This study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental treatment being tested in this study. The study is informational, and part of a larger program to understand and treat Hemophilia B with a potential experimental new therapy in the future. There is no obligation to agree to taking part in this future study. The study is looking to answer sev…
From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $305,992 in research payments for this study in 2025 (60 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Tyler W. Buckner, M.D. Hematology · Aurora, CO
- Michael Wang, MD Pediatric Hematology & Oncology · Aurora, CO
- Robert D. Bona, MD Hematology & Oncology · Farmington, CT
- Craig Kessler Hematology & Oncology · Washington, DC
- Tung T. Wynn, M.D. Pediatric Hematology & Oncology · Gainesville, FL
- Bhavya Doshi, M.D. Pediatric Hematology & Oncology · Atlanta, GA
- Mindy L. Simpson, M.D. Pediatric Hematology & Oncology · Chicago, IL
- Sanjay P. Ahuja, MD Pediatric Hematology & Oncology · Indianapolis, IN
- Steven W. Pipe, MD Pediatric Hematology & Oncology · Ann Arbor, MI
- Amy L. Dunn, MD Pediatric Hematology & Oncology · Columbus, OH
- Benjamin J. Samelson-jones, MD Pediatric Hematology & Oncology · Philadephia, PA
- Miguel A. Escobar, M.D. Hematology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $60,075
- Children's Hospital of Philadelphia, PA $58,382
- Uh Cleveland Medical Center, OH $40,010
- Rush University Medical Center, IL $34,264
- Georgetown University $28,800
- Regents of the University of Colorado $22,169
- The Research Instute at Nationwide Childrens Hospital $22,042
- University of Florida $17,410
- University of Michigan Health System, MI $11,105
- University of Texas Health Science Center at Houston $7,697
- The Research Institute at Nationwide Childrens Hospital $4,039
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.